MEDFUTURES, LLC
BELL, FLORIDA

The combination of POZEN Inc. and Tribute Pharmaceuticals Canada Inc. represents an important strategic transformation that created Aralez, a specialty pharmaceutical company with a compelling growth platform, from which we believe we can drive significant long-term value creation. Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ and TSX: ARZ) is a global specialty pharmaceutical company focused on delivering meaningful products to improve patients’ lives, while creating shareholder value by acquiring, developing and commercializing products primarily in cardiovascular and other specialty areas. Aralez’s Global Headquarters is in Ontario, Canada, the US Headquarters is in Princeton, NJ and the Ireland Headquarters is in Dublin, Ireland. Aralez has a competitive growth platform designed to help enable us to execute our growth strategy. It provides a diversified, growing revenue base and a geographic footprint across North America and Europe, with cardiovascular disease being its therapeutic anchor position, led by a management team with a proven track record and history of success. Our business model is focused on strategic priorities, which aim to grow a diversified business and deliver meaningful products that are capable of delivering sustainable sales growth and that offer financial and competitive advantages. We strive to maintain a lean, nimble and performance-oriented operating model with strong financial discipline that will allow us to build value organically and through acquisitions. A key accelerator to our business strategy involves seizing high potential growth opportunities through aggressive business development and licensing, with the goal of building on our anchor position in cardiovascular disease and expanding into other specialty therapeutic areas. The combination of POZEN Inc. and Tribute Pharmaceuticals represents an important strategic transformation, creating Aralez Pharmaceuticals, a specialty pharmaceutical company with a compelling growth platform. The Aralez portfolio of approved products is anchored in cardiovascular disease and plans for continued development and growth in this and other specialty areas. Aralez is focused on delivering meaningful products to improve patients’ lives while growing shareholder value in short, medium and long-term. Investor information such as Everything we do is inspired by our strong commitment to the Aralez mission, vision, and core values. Our journey into the future is guided by the principle that both “what” we do and “how” we do it differentiates our business and serves as the road map for our valued employees to achieve our goals and serve our patients. In doing so, we strive to provide maximum value to patients, employees, shareholders, and the healthcare community. MISSION Our Mission is to improve the lives of patients throughout the world by successfully identifying, developing, maximizing and commercializing innovative specialty pharmaceutical products. We are committed to the long-term success of our employees, creating value for shareholders and offering new treatment options to healthcare professionals for the welfare of our patients. Our Vision is to be the most successful and admired global specialty pharmaceutical company. – We encourage opportunities for creative thinking and appropriate risk-taking. We are resourceful and capable of providing innovative solutions that anticipate and embrace change for better outcomes. Our streamlined operating principles maximize an entrepreneurial environment that delivers value to shareholders and customers. – Our people are the core of our success. We believe the best solutions come from working together collaboratively. Our value of and respect for one another fosters a vibrant and nimble culture to attract and retain high performing people. Individuals are provided opportunities for development and are motivated to achieve their maximum potential. – We seek to earn the trust and respect of all those who interact with us. We hold ourselves to the highest operational, compliance and ethical standards. We never compromise on quality and business ethics. The combination of POZEN Inc. and Tribute Pharmaceuticals represents an important strategic transformation, creating Aralez Pharmaceuticals, a specialty pharmaceutical company with a compelling growth platform. Arthur S. Kirsch is Chairman of the Board of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 1, 2015 and on the Board since May 2004. He is chairman of the audit committee and a member of the compensation and governance/nominating committees. Mr. Kirsch has over 30 years of experience working in the equity capital markets and has extensive knowledge of the healthcare and life sciences field. Since 2005 he has been a Senior Advisor with GCA Savvian, LLC (formerly Perseus Group, LLC), an investment bank. Prior to GCA Savvian he was a founding member and managing director of Vector Securities, LLC, an investment and merchant banking firm. Mr. Adams is Chief Executive Officer and a Director of Aralez Pharmaceuticals Inc. and served in this role with the company’s predecessor, POZEN Inc., since June 1, 2015. Prior to joining the company, Mr. Adams served as Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc. from December 2011 until its acquisition by Endo International plc in January 2015 for $2.6 billion. Under his leadership, Auxilium transformed into a men’s healthcare company and broadened its portfolio from two to twelve through the strategic corporate acquisition of Actient Holding LLC and product in-licensing. Prior to joining Auxilium, Mr. Adams served as Chairman and Chief Executive Officer of Neurologix, Inc., a company focused on development of multiple innovative gene therapy development programs. Before Neurologix, Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. in May 2011 for $430 million. Prior to Inspire, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. from December 2006 until its acquisition by Dainippon Sumitomo Pharma Co. in February 2010 for $2.6 billion. Under his leadership, Sepracor conducted multiple strategic corporate development activities, including the in-licensing of seven products and out-licensing deals with two major pharmaceutical companies, prior to its acquisition by Dainippon Sumitomo Pharma Co.